tert-butyl (4R)-4-aminopentanoate | 426253-94-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (4R)-4-aminopentanoate
• 英文别名: (R)-tert-butyl 4-aminopentanoate；tert-butyl(4R)-4-aminopentanoate
• CAS: 426253-94-3
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: WAOWMAGPPDFHBR-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (4R)-4-aminopentanoate 在 盐酸 、 potassium tert-butylate 、 sodium cyanoborohydride 、 溶剂黄146 、 甲基磺酰氯 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 15.85h， 生成 1-allyl 4-methyl (2R)-2-methyl-3,6-dihydropyridine-1,4(2H)-dicarboxylate
  参考文献：
  名称：

  New Anti-MRSA and Anti-VRE Carbapenems; Synthesis and Structure-activity Relationships of 1.BETA.-Metyl-2-(thiazol-2-ylthio)carbapenems.

  摘要：

  发现新型抗微生物制剂，特别是针对耐药病原体引起的感染，是一项重要的目标。为了找到一种新的静脉注射碳青霉烯类抗生素，该抗生素具有强大的抗菌活性，尤其对耐甲氧西林葡萄球菌、耐万古霉素肠球菌和耐青霉素肺炎链球菌有效，我们合成了一系列在C-2位点带有噻唑-2-硫基的1β-甲基碳青霉烯类化合物。通过研究结构-活性关系，我们选定了SM-197436（27）、SM-232721（44）和SM-232724（41）进行进一步评估。

  DOI：

  10.7164/antibiotics.55.722
• 作为产物：
  描述：

  S-4-benzyloxycarbonylamino-5-hydroxy-pentanoic acid tert-butyl ester 在 palladium on activated charcoal 偶氮二异丁腈 、 四溴化碳 、 氢气 、 三正丁基氢锡 、 三苯基膦 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 3.83h， 生成 tert-butyl (4R)-4-aminopentanoate
  参考文献：
  名称：

  New Anti-MRSA and Anti-VRE Carbapenems; Synthesis and Structure-activity Relationships of 1.BETA.-Metyl-2-(thiazol-2-ylthio)carbapenems.

  摘要：

  发现新型抗微生物制剂，特别是针对耐药病原体引起的感染，是一项重要的目标。为了找到一种新的静脉注射碳青霉烯类抗生素，该抗生素具有强大的抗菌活性，尤其对耐甲氧西林葡萄球菌、耐万古霉素肠球菌和耐青霉素肺炎链球菌有效，我们合成了一系列在C-2位点带有噻唑-2-硫基的1β-甲基碳青霉烯类化合物。通过研究结构-活性关系，我们选定了SM-197436（27）、SM-232721（44）和SM-232724（41）进行进一步评估。

  DOI：

  10.7164/antibiotics.55.722

文献信息

• NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE
  申请人：Hidaka Hiroyoshi

  公开号：US20130274269A1

  公开（公告）日：2013-10-17

  The present invention provides a novel isoquinoline-6-sulfonamide derivative that is useful as a medicine. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the derivative or the salt, wherein R 1 and R 2 each independently represent a hydrogen atom, or the like; R 3 and R 4 each independently represent a hydrogen atom, an alkyl group, or the like; R 5 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted cycloalkyl group, an optionally substituted alkanoyl group, or the like; and A represents a linear or branched alkylene group having 2 to 6 carbon atoms.

  本发明提供了一种新型的异喹啉-6-磺酰胺衍生物，该衍生物可用作药物。本发明提供了一种由公式（1）表示的异喹啉-6-磺酰胺衍生物，其盐，或衍生物或盐的溶剂化物，其中R1和R2各自独立地代表氢原子或类似物；R3和R4各自独立地代表氢原子、烷基或类似物；R5代表氢原子、可选地取代的烷基、可选地取代的烯基、可选地取代的炔基、可选地取代的环烷基、可选地取代的烷酰基或类似物；A代表具有2至6个碳原子的直链或支链亚烷基。
• Novel beta-lactam compounds and process for producing the same
  申请人：——

  公开号：US20040102433A1

  公开（公告）日：2004-05-27

  1. A &bgr;-lactam compound of the formula [1]; 1 wherein R 1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R 2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y 1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y 2 is hydrogen, an alkyl, cyano, —C(R 3 )═NR 4 (wherein R 3 and R 4 are hydrogen, an amino, an alkyl, etc., or R 3 and R 4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.

  一种化学式为[1]的A &bgr;-内酰胺化合物，其中R1是低碳基，被羟基取代的低碳基; R2是氢，低碳基; X是O，S，NH; m和n为0至4，Y1是卤素，氰基，羟基，氨基，低碳基氧基，低碳基氨基，羧基，氨基甲酰基，低碳基等，Y2是氢，烷基，氰基，—C(R3)═NR4（其中R3和R4是氢，氨基，烷基等，或R3和R4可以相互结合形成5-至7成员杂环基的氮原子），或其药学上可接受的盐，或其非毒性酯，对革兰氏阳性菌，特别是对MRSA和MRCNS具有出色的抗菌活性。
• β-lactam compounds and process for producing the same
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：US07163936B2

  公开（公告）日：2007-01-16

  1. A β-lactam compound of the formula [1]; wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, —C(R3)═NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.

  一种β-内酰胺化合物，其化学式为[1]；其中R1为较低的烷基，一种被羟基取代的较低烷基；R2为氢，较低的烷基；X为O、S、NH；m和n为0至4，Y1为卤素、氰基、羟基、氨基、较低的烷氧基、较低的烷基氨基、羧基、氨基甲酰基、较低的烷基等；Y2为氢、烷基、氰基、—C(R3)═NR4（其中R3和R4为氢、氨基、烷基等，或R3和R4可能互相结合形成一个5至7元杂环基），或其药学上可接受的盐或非毒性酯，对革兰氏阳性菌，特别是MRSA和MRCNS具有优异的抗菌活性。
• NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：EP1340756A1

  公开（公告）日：2003-09-03

  1. A β-lactam compound of the formula [1];    wherein R1 is a lower alkyl, a lower alkyl substituted by a hydroxy; R2 is a hydrogen, a lower alkyl; X is O, S, NH; m and n are 0 to 4, Y1 is a halogen, cyano, a hydroxy, an amino, a lower alkyloxy, a lower alkylamino, a carboxy, a carbamoyl, a lower alkyl, etc., Y2 is hydrogen, an alkyl, cyano, -C(R3)=NR4 (wherein R3 and R4 are hydrogen, an amino, an alkyl, etc., or R3 and R4 may combine each other together with the nitrogen atom to form a 5- to 7-membered heterocyclic group), or a pharmaceutically acceptable salt thereof, or a non-toxic ester thereof, which has an excellent antibacterial activity against Gram-positive bacteria, especially against MRSA and MRCNS.

  1.一种式[1]的β-内酰胺化合物； 其中 R1 是低级烷基、被羟基取代的低级烷基；R2 是氢、低级烷基；X 是 O、S、NH；m 和 n 是 0 至 4；Y1 是卤素、氰基、羟基、氨基、低级烷氧基、低级烷氨基、羧基、氨基甲酰基、低级烷基等；Y2 是氢、烷基、氰基、-C(R3)＝NR4（其中 R3 和 R4 是氢、氨基、烷基等、或 R3 和 R4 可与氮原子相互结合形成 5 至 7 元杂环基团），或其药学上可接受的盐，或其无毒酯，对革兰氏阳性菌，尤其是 MRSA 和 MRCNS 具有优异的抗菌活性。
• Chemoenzymatic Dynamic Kinetic Resolution of Primary Amines Catalyzed by CAL-B at 38–40 °C
  作者：Florent Poulhès、Nicolas Vanthuyne、Michèle P. Bertrand、Stéphane Gastaldi、Gérard Gil

  DOI：10.1021/jo201256w

  日期：2011.9.2

  The (R)-selective chemoenzymatic dynamic kinetic resolution of primary amines was performed at 38-40 degrees C in MTBE, in good to high yields and with high enantiomeric excesses. These reactions associating CAL-B to octanethiol as radical racemizing agent were carried out in the presence of methyl beta-methoxy propanoate as acyl donor, under photochemical irradiation at 350 nm in glassware.